Do you believe in magic?

Journal of Practical Psychiatry and Behavioral Health

Volumn 3, Issue 2, 1997, Pages 99-103

  Preskorn, Sheldon H ^a,b  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE WICHITA   (United States)

^b University of Kansas School of Medicine Wichita Psychiatric Research Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0038787516     PISSN: 10765417     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Preskorn SH. Clinical pharmacology of selective serotonin reuptake inhibitors. Caddo, OK: Professional Communications, Inc.; 1996.
2. Sharp T., McQuade R., Bramwell S., Hjorth S. Effect of acute and repeated administration of 5-HT1A receptor agonists on 5-HT release in rat brain in vivo. Naunhyn Schmiedebergs Arch Pharmacol. 348(4): 339-46;1993.
3. Van den Hooff P., Galvan M. Actions of 5-hydroxytryptamine and 5-HT1A receptor ligands on rat dorso-lateral septal neurones in vitro. Br J Pharmacol. 106(4):893-9; 1992.
4. Grasby P., Sharp T., Moorman J., Grahame-Smith D. Comparison of the effect of buspirone and 1-(2-pyrimidinyl)piperazine on cerebral glucose utilization in the rat. Eur J Pharmacol. 230(1):41-6;1993.
5. Manahan-Vaughan D., Anwyl R., Rowan MJ. The azapirone metabolite 1-(2-pyrimidinyl) piperazine depresses excitatory synaptic transmission in the hippocampus of the alert rat via 5-HT1A receptors. Eur J Pharmacol 294(2-3):617-24;1995.
6. Blier P., Curet O., Chaput Y., de-Montigny C. Tandospirone and its metabolite, 1-(2-pyrimidinyl) piperazine-II. Effects of acute administration of 1-PP and long-term administration of tandospirone on noradrenergic neurotransmission. Neuropharmacology. 39(7):691-701;1991.
7. Done CJ., Sharp T. Biochemical evidence for the rgulation of central noradrenergic activity by 5-HT1A and 5-HT2 receptors: microdialysis studies in the awake and anaesthetized rat. Neuropharmacology. 33(3-4): 411-21; 1994.
8. Cao BJ., LI, WP., Antagonism of clonidine antinociception by buspirone and 1-(2-pyrimidinyl) piperazine. Eur J Pharmacol. 259(1):75-8:1994.
9. Martin P. 1-(2-pyrimidinyl)piperazine may alter the effects of the 5-HT1a agonist in the learned helplessness paradigm in rats. Psychopharmacology-Berl. 104(2):275-8; 1991.
10. Przegalinski E., Tatarczynska E., Chojnacka-Wojcik E. Antidepressant-like activity of ipsapirone, buspirone and gepirone in the forced swimming test in rats pretreated with proadifen. Journal of Psychopharmacology 4(4):204-9;1990.
11. Bakish D. Fluoxetine potentiation by buspirone: Three case histories. Can J Psychiatry. 36(10):749-50;1991.
12. Jaeobsen FM. Possible augmentation of antidepressant response by buspirone. J Clin Psychiatry. 52(5):217-20;1991.
13. Robillard M., Lieff S. Augmentation of antidepressant therapy by buspirone: Three geriatric case histories. Can J Psychiatry. 40(10):639-40;1995.
14. Joffe RT, Schuller DR. An open study of buspirone augmentation of serotonin reuptake inhibitors in refractory depression. J Clin Psychiatry. 54(7):269-71;1993.
15. Grady TA., Pigott TA., L'Heureux F., Murphy DL. Seizure associated with fluoxetine and adjuvant buspirone therapy. J Clin Psychopharmacol. 12(1):70-1;1992.
16. Lebert F., Pasquier F., Goudemand M., Petit H. Euphoria with buspirone after fluoxetine treatment. Am J Psychiatry. 150(1); 167;1993.
17. Sternbach H. The serotonin syndrome. Am J Psychiatry. 148:705-13; 1991.